Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from Puma Biotechnology and Seagen, Inc.

Patient, Provider, and Caregiver Connection™: Addressing Patient Concerns While Managing HER2+ Breast Cancer

Release Date: August 13, 2021
Expiration Date: August 13, 2022

Activity Overview

This video-based program is designed for health care professionals to explore the diagnosis and treatment of HER2-positive breast cancer through a unique perspective, putting the patient’s voice front and center. Patients and their caregivers lend their expertise to this program by sharing their journey living with HER2-positive breast cancer. This online activity focuses on the clinical presentation and diagnostic evaluation of early-stage and metastatic HER2-positive breast cancers and the efficacy and safety of HER2-targeted therapies recommended for treatment of patients in both of these disease settings.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Puma Biotechnology and Seagen, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, nurse practitioners, physicians’ assistants, nurses, and other health care professionals who treat or care for patients with HER2+ breast cancer. This activity will provide education to a broad multidisciplinary team who are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Evaluate recently reported clinical trial data that impact treatment options and therapeutic sequencing for patients with HER2-positive breast cancer
  • Outline strategies to maintain or improve patient quality of life and patient counseling during treatment for HER2-positive breast cancer
  • Assess optimal strategies to prevent and mitigate toxicities associated with HER2-directed therapy
  • Apply emerging data to clinical scenarios in the treatment of patients with HER2-positive breast cancer

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Joyce O’Shaughnessy, MD
Joyce O’Shaughnessy, MD
Celebrating Women Endowed Chair in Breast Cancer Research
Co-Chair, Breast Cancer Research Program
Chair, Breast Cancer Prevention Research
Baylor University Medical Center-Charles A. Sammons Cancer Center
The US Oncology Network
Dallas, TX

Disclosures: Consultant: AbbVie Inc., Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene Corporation, Clovis Oncology, Daiichi Sankyo, Eisai, G1 Therapeutics, Genentech, Gilead Sciences, GRAIL, Halozyme Therapeutics, Heron Therapeutics, Immunomedics, Ipsen Biopharmaceuticals, Lilly, Merck, Myriad, Nektar Therapeutics, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Prime Oncology, Roche, Samsung Bioepis, Sanofi, Seagen, Syndax Pharmaceuticals, Taiho Oncology, Takeda, Synthon.


Reva Basho, MD
Reva Basho, MD
Assistant Professor, Medicine
Co-Director, Women’s Cancer Program
Cedars-Sinai Samuel Oschin Cancer Center
Los Angeles, CA

Disclosures: Grant/Research Support: Merck, Seattle Genetics, Ichnos Biosciences; Consultant: Genomic Health, AstraZeneca, Biotheranostics, Pfizer; Speaker’s Bureau: Genentech, Seattle Genetics.

Marissa Marti, APRN, AGNP-C, AOCNP
Marissa Marti, APRN, AGNP-C, AOCNP
Nurse Practitioner
Breast Oncology
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, TX

Disclosures: Consultant: Novartis, Puma Biotechnology, Research to Practice, i3 health, Biotheranostics.


Cathy Carmody
Breast Cancer Survivor

Disclosures: Cathy Carmody has no relevant financial relationships with ineligible companies.

Melissa O’Neil
Breast Cancer Survivor

Disclosures: Melissa O’Neil has no relevant financial relationships with ineligible companies.


Marcie Coyne

Disclosures: Marcie Coyne has no relevant financial relationships with ineligible companies.

Brian O’Neil

Disclosures: Brian O’Neil has no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By